Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics (MCRB) announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and CEO, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently announced that SER-155 received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant, to treat hematological malignancies, from the US Food and Drug Administration. This designation was supported by Phase 1b placebo-controlled study results in patients undergoing allo-HSCT demonstrating that SER-155 was associated with a significant reduction in BSIs a significant reduction in systemic antibiotic exposure, and lower incidence of febrile neutropenia. In addition to allo-HSCT, bloodstream infections are a common and serious complication in many other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. Seres is actively seeking a partner to provide financial resources and other capabilities to more fully explore the development of SER-155 and additional pipeline candidates for these populations.